AriBio to unveil Phase 3 Alzheimer’s data at CTAD 2026
AriBio will present topline results from its pivotal Phase 3 POLARIS-AD trial of oral AR1001 at the CTAD conference in Boston on Nov. 16, 2026. The readout could clarify whether the once-daily drug can slow early Alzheimer’s disease and support a potential first FDA-approved oral disease-modifying therapy.
Why it matters: - AriBio’s Phase 3 readout is a key test for AR1001, a once-daily oral candidate aimed at slowing early Alzheimer’s disease. - Positive results could move AR1001 closer to becoming the first FDA-approved oral disease-modifying therapy for Alzheimer’s disease. - The topline data are part of a global clinical program with broad implications for patients, care partners and future treatment options.
What happened: - AriBio said topline results from the pivotal POLARIS-AD Phase 3 trial will be presented at the 19th Clinical Trials on Alzheimer’s Disease conference in Boston from Nov. 16-19, 2026. - Dr. Sharon Sha, chief of the Memory Disorders Division at Stanford University and global principal investigator of POLARIS-AD, will present the findings in the conference’s first oral communications session on Nov. 16 at 4:05 p.m. EST. - The presentation will cover 52-week efficacy and safety outcomes from the double-blind study. - CTAD highlighted POLARIS-AD among the major clinical trial readouts in this year’s program.
The details: - POLARIS-AD is a global, randomized, double-blind, placebo-controlled Phase 3 trial of AR1001 in people with early Alzheimer’s disease. - The study enrolled 1,535 participants across about 230 clinical sites in 13 countries. - Participants received AR1001 30 mg or placebo once daily for 52 weeks. - The primary endpoint is change from baseline to Week 52 on the Clinical Dementia Rating–Sum of Boxes, or CDR-SB. - The trial also measures cognition, daily functioning and Alzheimer’s-related biomarkers. - A total of 1,348 participants, or 88%, completed the 52-week treatment period. - More than 95% of eligible participants who finished the main study chose to enter the optional long-term extension study, where all participants receive AR1001. - AriBio will also present two posters at CTAD 2026: P515 on building an oral therapeutic franchise across Alzheimer’s disease and related dementia, and P135 on an AI-assisted review support tool for clinical operations and data reconciliation. - AR1001 is a blood-brain barrier-penetrant phosphodiesterase-5 inhibitor designed to enhance cyclic guanosine monophosphate signaling. - The company said Phase 2 data showed AR1001 was generally well tolerated, with a safety profile similar to placebo. - Phase 2 biomarker analyses showed reductions in plasma p-tau181, p-tau217 and GFAP at the 30 mg dose versus placebo.
Between the lines: - The CTAD slot signals that AriBio is positioning POLARIS-AD as a high-value clinical readout for the Alzheimer’s field. - The company is framing AR1001 as an oral alternative in a market where treatment options remain limited and long-term practicality matters. - The broader scientific case still depends on whether the Phase 3 data show meaningful clinical benefit, not just encouraging earlier-stage biomarker trends.
What's next: - AriBio will present the POLARIS-AD topline data on Nov. 16, 2026, during CTAD in Boston. - The company expects the presentation to inform discussion with the international research community. - If the readout is favorable, the next focus will likely shift to regulatory and development steps for AR1001. - AR1001 remains investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.
The bottom line: - AriBio is about to put its lead Alzheimer’s candidate in front of the field’s top researchers, and the results could determine whether AR1001 becomes a serious contender in oral disease-modifying therapy.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
American Food & Beverage Online
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.